National Brain Tumor Society Launches DNA Damage Response Consortium with Yale
Consortium seeks to advance underdeveloped area of brain cancer research, advance drug development, and improve treatment options for patients
Related Articles
Cilta-Cel Data Set a High Bar for Anito-Cel in Relapsed/Refractory Myeloma
Darren Pan, MD, discusses updates regarding cilta-cel and anito-cel for the treatment of patients with relapsed/refractory multiple myeloma.
Data for Elotuzumab Support Further Investigation in JAK Inhibitor–Based Combinations in Myelofibrosis
Safety and efficacy data for elotuzumab support its further investigation in the treatment of myelofibrosis.
Lutetium Lu 177 Vipivotide Tetraxetan Positioned for Earlier Use in mCRPC While Radium-223 Sequencing Requires Further Clarification
Qian (Janie) Qin, MD, discusses the current arsenal of radioligand therapies in metastatic castration-resistant prostate cancer.
KIM-1 Represents a Potential Biomarker for Outcomes and Response in RCC
KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.
FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL
The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia
Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.
Investigational Neoantigen Vaccines Target RCC Mutations and Drive Durable T-Cell Activity
David A. Braun, MD, PhD, discusses findings from a study of personalized neoantigen vaccines in patients with high-risk, resectable ccRCC.
Novel CAR T-Cell Therapy Could Pave the Way for Improvements in Advanced ccRCC Management
Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.
FDA Grants Priority Review to TAR-200 for BCG-Unresponsive High-Risk NMIBC
The FDA has granted priority review to TAR-200 for BCG-unresponsive, high-risk NMIBC with CIS, with or without papillary tumors.
DESTINY-Breast09 Data Spark Debate on Sequencing and Frontline Maintenance Strategies in HER2+ Breast Cancer
Laura Huppert, MD, discusses the implications of data with first-line T-DXd plus pertuzumab in HER2-positive metastatic breast cancer.